Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 2,434 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Arcutis Biotherapeutics Inc | ARQT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.06 | 0.67% | 9.00 | 08:47:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 8.94 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 69 | 2,434 | - | 1.76 - 15.21 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 08:46:59 | 66 | $ 9.00 | USD |
Arcutis Biotherapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 865.51M | 96.81M | - | 59.61M | -262.14M | -2.71 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Arcutis Biotherapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ARQT Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 10.015 | 10.38 | 8.435 | 9.52 | 2,580,539 | -1.02 | -10.13% |
| 1 Month | 9.39 | 13.17 | 8.435 | 10.53 | 2,998,679 | -0.39 | -4.15% |
| 3 Months | 5.92 | 13.17 | 5.38 | 9.41 | 4,345,279 | 3.08 | 52.03% |
| 6 Months | 2.52 | 13.17 | 1.76 | 5.73 | 4,770,839 | 6.48 | 257.14% |
| 1 Year | 13.97 | 15.21 | 1.76 | 6.17 | 3,065,626 | -4.97 | -35.58% |
| 3 Years | 30.58 | 36.45 | 1.76 | 9.15 | 1,333,442 | -21.58 | -70.57% |
| 5 Years | 23.05 | 40.88 | 1.76 | 10.20 | 995,744 | -14.05 | -60.95% |
Arcutis Biotherapeutics Description
| Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate, roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. |
